"We are an internationally recognized center for the diagnosis, treatment, and care in the field of corneal and refractive surgery. We, along with our research partner, Cornea Research Foundation of America, have conducted more than 160 studies including those that led to the FDA approval of LASIK. We are proud to be Indiana's first LASIK provider. For more than 30 years, we have utilized the latest technology while conducting ground-breaking research to provide cutting-edge services to our patients from all over the world. In addition to training over 600 doctors from around the world, our surgeons have performed more cornea transplants than any other practice in North America."

During the past decade, Price Vision Group conducted 29 clinical trials. In the 10-year time frame, 29 clinical trials started and 21 clinical trials were completed, i.e. on average, 72.4% percent of trials that started reached the finish line to date. In the past 5 years, 19 clinical trials started and 13 clinical trials were completed. i.e. 68.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Price Vision Group" #1 sponsor was "Price Vision Group" with 10 trials, followed by "Cornea Research Foundation of America" with 5 trials sponsored, "Glaukos Corporation" with 4 trials sponsored, "Kala Pharmaceuticals, Inc." with 3 trials sponsored and "Allergan" with 3 trials sponsored. Other sponsors include 17 different institutions and companies that sponsored additional 22 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Price Vision Group" #1 collaborator was "Cornea Research Foundation of America" with 2 trials as a collaborator, "National Eye Institute (NEI)" with 2 trials as a collaborator, "ActualEyes Inc." with 1 trials as a collaborator, "Allergan" with 1 trials as a collaborator and "HumanOptics AG" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Price Vision Group" are "Fuchs' Endothelial Dystrophy" (5 trials), "Keratoconus" (4 trials), "Bullous Keratopathy" (3 trials), "Cataract" (2 trials) and "Corneal Edema" (2 trials). Many other conditions were trialed in "Price Vision Group" in a lesser frequency.

Most popular intervention types in "Price Vision Group" are "Drug" (29 trials), "Device" (14 trials), "Other" (7 trials), "Combination Product" (4 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "KXL System" (2 trials), "LX201" (2 trials), "Netarsudil" (2 trials) and "ST266" (2 trials). Other intervention names were less common.

The vast majority of trials in "Price Vision Group" are 46 trials for "All" genders.

Currently, there are NaN active trials in "Price Vision Group". undefined are not yet recruiting, 9 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 24 completed trials in Price Vision Group, 1 suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Price Vision Group, 3 "Phase 1" clinical trials were conducted, 17 "Phase 2" clinical trials and 22 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 9 trials that are defined as “Not Applicable".